What's Happening?
Keenova, formerly known as Mallinckrodt, has announced that its drug Xiaflex has successfully met its objectives in a phase 3 trial for treating plantar fibromatosis, a condition characterized by non-cancerous growths on the feet. The trial, known as STRIDE,
involved 436 patients and demonstrated a statistically significant improvement in pain management compared to a placebo. Xiaflex, already approved for Dupuytren's contracture and Peyronie's disease, could potentially expand its market to include approximately 300,000 new patients annually if approved for this new indication. The company plans to file for approval by the end of the year.
Why It's Important?
The successful trial of Xiaflex for plantar fibromatosis represents a significant advancement in treatment options for this debilitating condition, which currently relies on orthotics, physical therapy, and surgery in severe cases. Approval of Xiaflex could provide a non-surgical alternative, improving quality of life for patients and potentially reducing healthcare costs associated with surgical interventions. For Keenova, this approval would not only expand its market reach but also solidify its position in the pharmaceutical industry, given that Xiaflex already accounts for a substantial portion of its revenue.
What's Next?
Keenova is expected to file for regulatory approval for Xiaflex in treating plantar fibromatosis by the end of the year. If approved, the company will likely focus on marketing strategies to reach the estimated 300,000 potential new patients annually. Additionally, Keenova is conducting further research on Xiaflex for other conditions, such as hammer toe, with a phase 3 trial scheduled to begin later this year. The outcome of these trials could further expand the drug's applications and market potential.
